Nevertheless, these studies suggest promising futures for individuals with mutations in genes of the leptin/melanocortin pathway but, as discussed in the remainder of the manuscript, reinforce the enormous challenge lying ahead if therapies are to be developed for individuals with syndromic or polygenic obesity. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.